SCHEMBL30967598

SCHEMBL30967598

C#CCN(C)CCCC[C@@H](CN1CCn2c(cc3c(OCC(F)(F)F)nccc32)C1=O)Nc1nccc2ccc(-c3noc(C)n3)cc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30967521 1.00 — —
SCHEMBL30967641 0.89 KIFC1 (0.31) —
SCHEMBL30967635 0.88 GPR119 (0.30) —
SCHEMBL30967622 0.86 HDAC1 (0.31) —
SCHEMBL30967660 0.86 HDAC1 (0.31) —
SCHEMBL30967523 0.80 STAT3 (0.31) —
SCHEMBL30967624 0.80 BTK (0.33) —
SCHEMBL30967538 0.80 CACNA2D1 (0.32) —
SCHEMBL30967454 0.78 — —
SCHEMBL30967562 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615838-A1 SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
WO-2024099898-A1 SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS MERCK PATENT GMBH (DE) 2024-05-16 — — WO disclosed
Send feedback